INS and fatty liver disease: In addition to its effects on insulin and glucagon, GLP-1 exhibits a wide range of actions, including promoting insulin sensitivity in the adipose tissue, stimulating energy expenditure and fat breakdown, reducing hepatic steatosis and liver lipid content, and delaying gastric emptying.